2006
DOI: 10.1007/s00280-006-0211-z View full text |Buy / Rent full text
|
|

Abstract: A highly sensitive HPLC/UV method for the quantification of SHetA2 in plasma has been developed to support pharmacokinetics of SHetA2 in the mouse. Pharmacokinetic behaviors of this drug appear to be favorable for future development.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
1
1
1
2
33
0

Year Published

2006
2006
2013
2013

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

2
33
0
Order By: Relevance
“…The efficacy, toxicity, pharmacokinetics and formulation of SHetA2 are currently being evaluated in the National Cancer Institute's (NCI's) Rapid Access to Intervention Development (RAID) program (Application 196, Compound NSC 726189). The RAID pharmacokinetic studies demonstrated that micromolar concentrations of SHetA2 can be achieved and maintained in mice [35] indicating that concentrations sufficient to differentially induce apoptosis in cancer cells over normal cells can be targeted in clinical trials.…”
Section: Discussionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 100,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…The efficacy, toxicity, pharmacokinetics and formulation of SHetA2 are currently being evaluated in the National Cancer Institute's (NCI's) Rapid Access to Intervention Development (RAID) program (Application 196, Compound NSC 726189). The RAID pharmacokinetic studies demonstrated that micromolar concentrations of SHetA2 can be achieved and maintained in mice [35] indicating that concentrations sufficient to differentially induce apoptosis in cancer cells over normal cells can be targeted in clinical trials.…”
Section: Discussionmentioning
“…The efficacy, toxicity, pharmacokinetics, and formulation of SHetA2 were evaluated in the National Cancer Institute's Rapid Access to Intervention Development (RAID) program (Application 196, Compound NSC 726189) and now in the Rapid Access to Preventive Intervention Development (RAPID) program. The RAID pharmacokinetic studies showed that micromolar concentrations of SHetA2 can be achieved in mice (19), indicating that concentrations sufficient to differentially induce apoptosis in cancer cells over normal cells can be targeted in clinical trials.…”
Section: Discussionmentioning
“…This in vitro study however, suffers from the same limitations as the clinical studies in the rarity of uterine cancer cell lines and patients with MMT and sarcoma histologies. SHetA2 decreased the survival of all three cell lines at physiologically achievable concentrations [16], but did not enhance their sensitivities to the chemotherapeutic agents. Similar to the differential effect of SHetA2 previously observed in ovarian cancer cell lines in comparison to normal and benign cultures [10,13], two of the three uterine cancer cell lines were more sensitive to SHetA2 in comparison to normal endometrial cells.…”
Section: Resultsmentioning